Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.

Slides:

Advertisements

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Advertisements

Fig. 1. TP is highly expressed in myeloma.

Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.

LTB4 production is elevated in preclinical and clinical lymphedema

Fig. 6. Sh-lantibiotics are commonly found on healthy human skin and synergize with a host AMP. Sh-lantibiotics are commonly found on healthy human skin.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 2. Increased Aβ plaque load in 16-month-old APP/PS1;C3 KO mice.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 4. BET bromodomain inhibition suppresses transactivation of shared transcriptional networks across HF models. BET bromodomain inhibition suppresses.

Fig. 3. Structure of ALS-associated RNA binding proteins.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Fig. 4 Bacterial taxonomic groups that discriminate among RYGB-, SHAM-, and WMS-derived samples. Bacterial taxonomic groups that discriminate among RYGB-,

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 6. Pathway analysis of CMLD

Fig. 2. GPC3 expression in normal and tumor tissues.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Fig. 1. Aberrant JNK pathway activation in mouse models of ALS and in spinal cord tissue from patients with sporadic ALS. Aberrant JNK pathway activation.

Dot plots of trisomic versus fetal fractions for cohorts 1 and 2

Identification of bioactive compounds modulating STING activation

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 8 TLR8 exacerbates disease in the BLM-induced fibrosis model.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 2. Pathways differentially regulated in patients with early Lyme disease and STARI. Pathways differentially regulated in patients with early Lyme.

Fig. 7. Gait training session overground with MGA or on a treadmill with upward support. Gait training session overground with MGA or on a treadmill with.

Fig. 2. Resistance to S63845-induced apoptosis through loss of BAK or elevated BCL-XL. Resistance to S63845-induced apoptosis through loss of BAK or elevated.

Fig. 1. Genomic landscape of serial tumor biopsies and genomic and immune correlates of treatment response. Genomic landscape of serial tumor biopsies.

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 2. Top nine proteins differentially expressed between BA and IHC.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Volume 29, Issue 5, Pages (May 2016)

Fig. 3 Rank stability of final models.

Fig. 2 ALRN-6924 rapidly increases transcription at the p21 locus and affects its bursting dynamics. ALRN-6924 rapidly increases transcription at the p21.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig F-FGln shows uptake in human gliomas undergoing progression.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 4 cTFH1 cells correlate with a boosting of influenza-specific memory B cells. cTFH1 cells correlate with a boosting of influenza-specific memory B.

Volume 26, Issue 12, Pages e5 (March 2019)

Ingenuity pathway analysis of the genes enriched in both 96-h-induced MMs and human ccRCC. Ingenuity pathway analysis of the genes enriched in both 96-h-induced.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Misfolding mutations impair the BRCA1 nuclear aggregation in yeast and the BRCA1 nuclear localization in human cells. Misfolding mutations impair the BRCA1.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Enrichment of KEGG pathways in microbial genes in different samples.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

Overall gene expression in monocyte subsets in patients and controls.

Fig. 6. Sh-lantibiotics are commonly found on healthy human skin and synergize with a host AMP. Sh-lantibiotics are commonly found on healthy human skin.

High-risk neuroblastoma molecular subtypes classification and inference of master regulators. High-risk neuroblastoma molecular subtypes classification.

Fig. 1. Dysbiosis of the skin microbiome in AD is associated with S

Driver pathways and key genes in OSCC

Integrated analysis of gene expression and copy number alterations.

Transcriptome traits and clinical characteristics of TME phenotypes in the ACRG cohort. Transcriptome traits and clinical characteristics of TME phenotypes.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

Presentation transcript:

Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent cohort. (A) Boxplots summarize burden of copy number gain or loss in three patient subgroups from the Van Allen cohort: clinical benefit, long-term survival with no clinical benefit, and minimal or no clinical benefit; median values (lines) and interquartile range (whiskers) are indicated. P values were calculated using two-sided Mann-Whitney U test (P = 0.016 for burden of copy number loss in clinical benefit versus minimal or no clinical benefit and P > 0.05 for all others). (B) Gene set enrichment analysis (GSEA) results show top enriched KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways from down-regulated genes (blue bars) and up-regulated genes (red bars) in high burden of copy number loss group versus low burden of copy number loss group (false discovery rate–adjusted P < 0.001). (C) Proportions of patients with clinical benefit, long-term survival with no clinical benefit, and minimal or no clinical benefit were calculated within each of the four patient subgroups: high mutational load and low burden of copy number loss, high mutational load and high burden of copy number loss, low mutational load and low burden of copy number loss, and low mutational load and high burden of copy number loss. The numbers in parentheses indicate the number of patients with different levels of response (clinical benefit, long-term survival, and no clinical benefit) out of the total number of patients in each of the four patient subgroups. Whijae Roh et al., Sci Transl Med 2017;9:eaah3560 Published by AAAS